Re‐Irradiation for the Progressive Pediatric Diffuse Intrinsic Pontine Glioma: A Report on 109 Children From a Single Center
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31587 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Mohamed Saad Zaghloul und 7 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: Brain Stem Neoplasms, Diffuse Intrinsic Pontine Glioma, Re-Irradiation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Diffuse intrinsic pontine glioma (DIPG) is a challenging pediatric tumor that frequently progresses within the first year following local radiotherapy. However, several small studies have suggested that re‐irradiation may improve quality of life and extend overall survival. Patients and Methods This retrospective study included 109 children who experienced disease progression ≥3 months after their initial radiotherapy, and subsequently received re‐irradiation at a single institution. These patients were compared with a cohort of 60 children, meeting the same criteria, who were treated before adopting the re‐irradiation policy and received only the best supportive care (BSC). Most of the re‐irradiated children (94%) received first radiation dose as hypofractionation (39 Gy/13 fractions).
Results
The re‐irradiation group demonstrated significantly higher overall survival (OS) rates after the first progression, with a 6‐month OS of 42% (95% CI: 34%–53%) compared to 16% (95% CI: 8.9%–32%) in the BSC group ( p < 0.001). Re‐irradiation reduced the hazard of death by more than half (HR = 0.45, p < 0.001). Clinical response ( p < 0.001) and radiological response ( p = 0.016) were significant predictors of improved survival. While the time from initial radiotherapy to progression ( p = 0.059) and higher re‐irradiation doses ( p = 0.074) were associated with improved OS, these factors did not reach statistical significance but may represent potential prognostic indicators.
Conclusion
Re‐irradiation improved the OS in children with progression of DIPG and alleviated their signs and symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Radiation Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
- Radiation Oncology Department, Children's Cancer Hospital, Cairo, Egypt.
- The Institute of Cancer Research, London, UK.
- Radiology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
- Radiology Department, Children's Cancer Hospital, Cairo, Egypt.
- Pediatric Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
ORCID-Profile: Mohamed Saad Zaghloul, Moatssem Al Ayadi, Engy S Todary
Zitieren
APA
Zaghloul, M. S., Bishr, M. K., Refaat, A., Hemaly, A. E., Ayadi, M. A., Ahmed, S., Maher, E., & Todary, E. S. (2025). Re‐Irradiation for the Progressive Pediatric Diffuse Intrinsic Pontine Glioma: A Report on 109 Children From a Single Center. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31587
Vancouver
Zaghloul MS, Bishr MK, Refaat A, Hemaly AE, Ayadi MA, Ahmed S, et al. Re‐Irradiation for the Progressive Pediatric Diffuse Intrinsic Pontine Glioma: A Report on 109 Children From a Single Center. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31587
BibTeX
@article{Zaghloul2025,
author = {Zaghloul, Mohamed Saad and Bishr, Mai K and Refaat, Amal and Hemaly, Ahmed El and Ayadi, Moatssem Al and Ahmed, Soha and Maher, Eslam and Todary, Engy S},
title = {Re‐Irradiation for the Progressive Pediatric Diffuse Intrinsic Pontine Glioma: A Report on 109 Children From a Single Center},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31587}
}
EUVIMED